Abstract | Background: Objectives: To describe our experience with the diagnosis and treatment of adult patients with AD-HIES induced by DN-STAT3 variants. Methods: The medical records of adult patients (>18 years) treated at the Allergy and Clinical Immunology Clinic of Hadassah Medical Center, Jerusalem, Israel, were retrospectively analyzed. Immune and genetic workups were used to confirm diagnosis. Results: Discussion:
Dupilumab can be used safely as a biotherapy for atopic dermatitis in these patients as it can effectively alleviate eczema-related symptoms. Immunologists and dermatologists treating AD-HIES adult patients should be aware of demodicosis as a possible manifestation. DN-STAT3 variants in DBD do not hamper STAT3 phosphorylation.
|
Authors | Oded Shamriz, Limor Rubin, Amos J Simon, Atar Lev, Ortal Barel, Raz Somech, Maya Korem, Sigal Matza Porges, Tal Freund, David Hagin, Ben Zion Garty, Amit Nahum, Vered Molho Pessach, Yuval Tal |
Journal | Frontiers in immunology
(Front Immunol)
Vol. 13
Pg. 1044933
( 2022)
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 36605204
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Shamriz, Rubin, Simon, Lev, Barel, Somech, Korem, Matza Porges, Freund, Hagin, Garty, Nahum, Molho Pessach and Tal. |
Chemical References |
- STAT3 Transcription Factor
- STAT3 protein, human
|
Topics |
- Adult
- Humans
- Male
- Abscess
- Dermatitis, Atopic
(drug therapy, genetics)
- Eczema
- Job Syndrome
(diagnosis, genetics, therapy)
- Retrospective Studies
- STAT3 Transcription Factor
(genetics, metabolism)
- Female
|